- US Debating What to Do With Billions of TARP Money Left
- For Video Game Makers, Stakes Are High for Holidays
- Is BofA Considering Jon Corzine for Top Job?
- In Charity Tax Filing, a Real Glimpse of Goldman Sachs
- 30 Year Mortgage Rate Falls Again; Lowest In Five Weeks
- No Near-Term Inflation Threat: Fed's Plosser
- US Mortgage Refinancing Up; Buying Demand Sinks
- Intel Agrees to Pay AMD $1.25 Billion to Settle Disputes
- Ford, Hyundai, Audi Gaining Consumer Interest
- Busch: Another Obama Opportunity
- Light the Lights! Buffett and Gates Prepare to Answer Students' Questions at Columbia
- Farrell: Retailers?
- A Public Hearing That Isn't Public
- Boise State's Brilliant Stock Plan
- Apple's Global Retail Invasion
- Intel Settles; AMD Settles the Score
- For Video Game Makers, Stakes Are High for The Holidays
- Schork: Nat Gas Bulls Need a Snow Day
MOST SHARED
- Jobless Claims Post Another Drop as Picture Improves
- Obama Plans Jobs Summit But Not Second Stimulus
- Wal-Mart Holiday Forecast Light, Profit Beats
- A Public Hearing That Isn't Public
- "Friending" Big Pharma
- Obama Most Powerful Person in World: Forbes
- Meet The Leaders of the New Retail Revolution
- Pricier Beer Helps AB InBev Operating Profit
- Activision Says 'Call of Duty' Sets Launch Record
- US Will Borrow Less as Banks Pay Back Funds: Geithner
Text Size 
Shares of CV Therapeutics plummeted [CVTX
Loading...
()
] following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
Wednesday's drop came on top of the shares losing more than a quarter of their value in after-market trading Tuesday.
There was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.
CV Therapeutics said it believes the data could support expansion of the drug's approved uses to be included as a first choice treatment for angina. It is currently approved to treat chronic angina in patients who have not achieved an adequate response with other drugs.
Print
Email
- Billboard allows music lovers to watch concerts for free online, with five different camera angles.
- US real estate prices have fallen dramatically, but some places are still doing well. See the best-performing zip codes this year.
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
- A European dating site finds lovelorn singles from one specific country to be uglier than any other. Who is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- Just in time for the holidays, the Triumph company of Japan offers the latest innovation in women’s undergarments.
Data is a real-time snapshot *Data is delayed at least 15 minutes